[Tc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: extensive bone metastases or prior myelotoxic therapies
I · Intervention 중재 / 시술
[Tc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve and RLT eligibility (interval: 26
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Spatial mismatch was associated with no significant myelotoxicity, whereas high congruence may increase the risk. No fixed thresholds currently exist; thus, this method should be regarded as a supplementary tool in complex cases and future studies are needed to define the critical bone marrow volume.
[PURPOSE] Radioligand therapy (RLT) targeting PSMA (prostate-specific membrane antigen) has transformed the treatment of metastatic castration-resistant prostate cancer (mCRPC).
APA
Kunte SC, Delker A, et al. (2025). [Tc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer.. European journal of nuclear medicine and molecular imaging, 52(12), 4446-4455. https://doi.org/10.1007/s00259-025-07319-7
MLA
Kunte SC, et al.. "[Tc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer.." European journal of nuclear medicine and molecular imaging, vol. 52, no. 12, 2025, pp. 4446-4455.
PMID
40325260 ↗
Abstract 한글 요약
[PURPOSE] Radioligand therapy (RLT) targeting PSMA (prostate-specific membrane antigen) has transformed the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, bone marrow depletion remains a common side effect, particularly in patients with extensive bone metastases or prior myelotoxic therapies. This study evaluated [Tc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve to guide myelotoxic treatment decisions.
[METHODS] Ten mCRPC patients with extensive osseous tumor load on [F]F-PSMA PET/CT underwent [Tc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve and RLT eligibility (interval: 26.6 ± 18.5 days). Visual comparison of both modalities evaluated tumor-bone marrow overlap. Patients without significant co-localization received RLT ([Lu]Lu-PSMA or [Ac]Ac-PSMA) with laboratory monitoring before and between the cycles.
[RESULTS] No significant co-localization between viable bone marrow and PSMA-positive metastases was observed in 9/10 (90.0%) patients. Two other patients were excluded from RLT due to contraindications. Of the remaining seven patients, 2/7 (28.6%) underwent subsequent [Lu]Lu-PSMA therapy, 2/7 (28.6%) [Ac]Ac-PSMA therapy and 2/7 (28.6%) [Ac]Ac-[Lu]Lu-PSMA therapy. 1/7 (14.3%) received a single cycle of [Lu]Lu-PSMA, which was then followed by [Ac]Ac-PSMA therapy. Follow-up laboratory results showed no significant changes from baseline (p > 0.05).
[CONCLUSION] [Tc]Tc-antigranulocyte scintigraphy may support the assessment of bone marrow reserve in patients with extensive bone metastases. Spatial mismatch was associated with no significant myelotoxicity, whereas high congruence may increase the risk. No fixed thresholds currently exist; thus, this method should be regarded as a supplementary tool in complex cases and future studies are needed to define the critical bone marrow volume.
[METHODS] Ten mCRPC patients with extensive osseous tumor load on [F]F-PSMA PET/CT underwent [Tc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve and RLT eligibility (interval: 26.6 ± 18.5 days). Visual comparison of both modalities evaluated tumor-bone marrow overlap. Patients without significant co-localization received RLT ([Lu]Lu-PSMA or [Ac]Ac-PSMA) with laboratory monitoring before and between the cycles.
[RESULTS] No significant co-localization between viable bone marrow and PSMA-positive metastases was observed in 9/10 (90.0%) patients. Two other patients were excluded from RLT due to contraindications. Of the remaining seven patients, 2/7 (28.6%) underwent subsequent [Lu]Lu-PSMA therapy, 2/7 (28.6%) [Ac]Ac-PSMA therapy and 2/7 (28.6%) [Ac]Ac-[Lu]Lu-PSMA therapy. 1/7 (14.3%) received a single cycle of [Lu]Lu-PSMA, which was then followed by [Ac]Ac-PSMA therapy. Follow-up laboratory results showed no significant changes from baseline (p > 0.05).
[CONCLUSION] [Tc]Tc-antigranulocyte scintigraphy may support the assessment of bone marrow reserve in patients with extensive bone metastases. Spatial mismatch was associated with no significant myelotoxicity, whereas high congruence may increase the risk. No fixed thresholds currently exist; thus, this method should be regarded as a supplementary tool in complex cases and future studies are needed to define the critical bone marrow volume.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.